As the industry enters a transformative era, new developments from the Trump administration and shifting patient expectations are driving life sciences organizations to reimagine how patients receive their therapies. Direct-to-consumer (DTC) models are quickly gaining traction as both a compliance response and a strategic path to enhance affordability, streamline access and meet patients, healthcare providers (HCPs) and pharmacies where they are.
In this Drug Channels Institute article, Vice President of Business Development Jordan Armstrong discusses the circumstances under which DTC models are most effective, the advantages they can deliver in terms of affordability, patient experience and data visibility, as well as the risks they pose in areas such as regulation and stakeholder dynamics. Armstrong also shares practical guidance for how life sciences organizations can build and sustain programs that are compliant, scalable and patient-centric.
Drug Channels Institute is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.